The study hit its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) compared to placebo plus XTANDI
The company announced positive topline data from the Phase 3 ADorable-1 trial
The trial will enroll up to 42 patients in Finland across four cohorts
One task, one interaction, one pair, experts advocate
The conflict is also triggering a widening public health emergency
Nearly 12 million people are estimated to be living with glaucoma, making the country one of the worst affected globally
Gazyva/Gazyvaro outperformed placebo across all key and secondary endpoints
Fenebrutinib has the potential to become the first and only high-efficacy oral, brain-penetrant treatment for both RMS and PPMS, showing a profound benefit on relapsing and progressive disease biology
NCFB is a chronic lung condition where damaged airways cause persistent coughing and mucus production
The recommendation is based on new data from continuous safety monitoring of medicines in the EU
Subscribe To Our Newsletter & Stay Updated
